Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain

by Carlos Rubio-Terrés, Ruth Graefenhain de Codes, Darío Rubio-Rodríguez, Thomas Evers, Santiago Grau Cerrato

Budget Impact of Rivaroxaban for the Prevention of Thromboembolic Events after Hip or Knee Replacement in Spain

by Xavier Granero Xiberta, Antonio Murcia, José Ricardo Troncoso Durán, Claudio Gómez Zubeldia, Aleix Llorac Moix, Ruth Graefenhain De Codes, Maria Giovana Ferrario, Luis Lizán

Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain

by Santiago Moreno Guillen, Juan Emilio Losa García, Juan Berenguer Berenguer, José Manuel Martínez Sesmero, Santiago Cenoz Gomis, Ruth Graefenhain, David Lopez Sanchez-Cambronero, Francisco Javier Parrondo Garcia
Published 2017-09-01